Company intelligence / Profile preview

NeuroQore

Silicon Valley, California, United Statessosv.com ↗

Ownership: Private
Development stage: Commercial

Overview

NeuroQore has developed a proprietary rTMS-based neuromodulation device that delivers rapid and targeted magnetic pulses to modulate dysfunctional brain circuits associated with major depressive disorder and suicidality. The company claims faster onset and longer-lasting effects compared to traditional TMS devices. In early clinical studies, they reported high remission rates in drug-resistant depression patients. As of February 2024, their technology received FDA clearance for use in treating major depressive disorder.

Therapeutic areas: Psychiatry
Modalities: Device (Transcranial magnetic stimulation device)Non-pharmacological therapy
Industry: Therapeutic Medical Devices

Partnerships

Ontario Brain Institute (funding/support/collaboration)SOSV/IndieBio accelerator partnership/support

Beyond the preview

Go deeper on NeuroQore.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuroQore.

Explore the full profile